| Delaware | 35-2415390 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | 
| Sarah K. Solum Freshfields Bruckhaus Deringer US LLP 855 Main Street Redwood City, California 94063 Telephone: (650) 618-9250 | Scott Chaplin Chief Legal Officer PhenomeX Inc. 5858 Horton Street, Suite 320 Emeryville, California 94608 Telephone: (510) 858-2855 | 
| Large accelerated filer | ☐ | Accelerated filer | ☐ | 
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | 
| Emerging growth company | ☐ | 
| Item 3. | Incorporation of Documents by Reference. | 
| a. | The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on February 23, 2023 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). | 
| b. | The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-39388) filed with the Commission on
                    July 14, 2020 under Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description. | 
| c. | The Registrant’s Current Reports on Form 8-K, as filed with the Commission on January 26, 2023, February 14, 2023, March 6, 2023 and March 21, 2023. | 
| Item 4. | Description of Securities. | 
| Item 5. | Interests of Named Experts and Counsel. | 
| Item 6. | Indemnification of Directors and Officers. | 
| • | any breach of the director’s duty of loyalty to us or our stockholders; | 
| • | any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; | 
| • | any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or | 
| • | any transaction from which the director derived an improper personal benefit. | 
| • | we shall indemnify our directors and officers to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; | 
| • | we shall advance expenses to our directors and officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and | 
| • | the rights provided in our Bylaws are not exclusive. | 
| Item 7. | Exemption from Registration Claimed. | 
| Item 8. | Exhibits. | 
| Incorporated by  Reference | FiledHerewith | |||||||
| Exhibit Number | Exhibit Description | Form | Date | Number | ||||
| Amended and Restated Certificate of Incorporation of Berkeley Lights, Inc. | 8-K | 7-21-20 | 3.1 | |||||
| Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Berkeley Lights, Inc. | 8-K | 3-21-23 | 3.1 | |||||
| Amended and Restated Bylaws of PhenomeX Inc. | 8-K | 3-21-23 | 3.2 | |||||
| Form of Common Stock Certificate. | S-1/A | 7-13-20 | 4.2 | |||||
| Fifth Amended and Restated Investors’ Rights Agreement, dated March 28, 2018, by and between Berkeley Lights, Inc. and the investors listed therein. | S-1 | 6-26-20 | 4.3 | |||||
| Opinion and Consent of Freshfields Bruckhaus Deringer US LLP. | X | |||||||
| Consent of KPMG LLP, Independent Registered Public Accounting Firm. | X | |||||||
| Consent of Deloitte and Touche LLP, Independent Registered Public Accounting Firm. | X | |||||||
| Consent of Freshfields Bruckhaus Deringer US LLP (contained in Exhibit 5.1). | X | |||||||
| Power of Attorney (included on the signature page of this Registration Statement). | X | |||||||
| IsoPlexis Corporation 2014 Stock Plan. | X | |||||||
| Form of Notice of Grant under the IsoPlexis Corporation 2014 Stock Plan. | X | |||||||
| Calculation of Filing Fee Table. | X | |||||||
| # | Indicates management contract or compensatory plan. | 
| Item 9. | Undertakings | 
| (a) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: | 
| (i) | To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; | 
| (ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
                  represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not
                  exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes
                  in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and | 
| (iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. | 
| (b) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered
                  therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. | 
| (c) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. | 
| (d) | That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a
                  primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such
                  purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: | 
| (i) | Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424; | 
| (ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant; | 
| (iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned
                  Registrant; and | 
| (iv) | Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser. | 
| By: | /s/ Siddhartha Kadia, Ph.D. | |
| Name: | Siddhartha Kadia, Ph.D. | |
| Title: | Chief Executive Officer | |
| Signature | Title | Date | ||
| Chief Executive Officer and Director | March 21, 2023 | |||
| Siddhartha Kadia, Ph.D. | (Principal Executive Officer) | |||
| /s/ Mehul Joshi | Chief Financial Officer | March 21, 2023 | ||
| Mehul Joshi | (Principal Financial Officer) | |||
| /s/ J. Paul McClaskey | Chief Accounting Officer | March 21, 2023 | ||
| J. Paul McClaskey | (Principal Accounting Officer) | |||
| /s/ Gregory Lucier | Chairman of the Board | March 21, 2023 | ||
| Gregory Lucier | ||||
| /s/ John Chiminski | Director | March 21, 2023 | ||
| John Chiminski | ||||
| /s/ Jessica Hopfield, Ph.D. | Director | March 21, 2023 | ||
| Jessica Hopfield, Ph.D. | ||||
| /s/ Igor Khandros, Ph.D. | Director | March 21, 2023 | ||
| Igor Khandros, Ph.D. | ||||
| /s/ Michael Moritz | Director | March 21, 2023 | ||
| Michael Moritz | ||||
| /s/ Elizabeth Nelson | Director | March 21, 2023 | ||
| Elizabeth Nelson | ||||
| /s/ James Rothman, Ph.D. | Director | March 21, 2023 | ||
| James Rothman, Ph.D. |